Maximum Dose of Retatrutide
The maximum recommended dose of retatrutide is 12 mg administered subcutaneously once weekly.
Dosing Algorithm
Based on the most recent clinical trial data, retatrutide follows a structured dose escalation protocol 1, 2, 3:
Starting and Escalation Protocol
- Initial dose: 2 mg subcutaneously once weekly
- Escalation schedule: Gradual titration upward based on tolerability
- Maximum maintenance dose: 12 mg once weekly
The pivotal phase 2 and phase 3 trials consistently used 12 mg as the highest dose studied, with a starting dose of 2 mg to mitigate gastrointestinal side effects 1, 2, 3. This gradual escalation approach (starting at 2 mg rather than 4 mg) was specifically designed to reduce the frequency and severity of dose-related adverse events, particularly nausea, vomiting, and diarrhea.
Clinical Context
The 12 mg dose demonstrated the most robust efficacy across multiple outcomes:
- Type 2 diabetes: HbA1c reduction of -2.02% at 24 weeks and -1.94% at 40 weeks 3, 1
- Weight loss in obesity: 24.2% reduction at 48 weeks 2
- Metabolic dysfunction-associated steatotic liver disease (MASLD): 82.4% relative reduction in liver fat at 24 weeks 4
Important Caveats
The dose-response relationship is clear: higher doses (8 mg and 12 mg) consistently outperform lower doses (1 mg, 4 mg) across glycemic control, weight reduction, and metabolic parameters 1, 2, 3. However, gastrointestinal adverse events are dose-dependent and most frequent at the 12 mg dose, though they remain predominantly mild-to-moderate in severity and tend to subside over time 1, 2.
The starting dose of 2 mg with gradual escalation is critical - studies that used a 4 mg starting dose showed higher rates of gastrointestinal side effects compared to those starting at 2 mg 2, 3. This slower titration strategy improves tolerability without compromising long-term efficacy.
Monitoring Considerations
While on retatrutide, particularly at higher doses:
- Heart rate: Dose-dependent increases peak at 24 weeks then decline 2
- Gastrointestinal symptoms: Most common in first 12-24 weeks, typically resolve with continued therapy 1, 2
- Discontinuation rates: Only 2-5% due to adverse events at the 12 mg dose 1
No dose adjustments are required for renal impairment based on the available evidence, though this was not explicitly studied in severe renal dysfunction 1, 3.